PHP
PRCT icon

Parkman Healthcare Partners’s Procept Biorobotics PRCT Stock Holding History

Parkman Healthcare Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-67,252
Closed -$1.91M – 103
2023
Q1 		$1.91M Sell
67,252
-45,066
-40% -$1.59M 0.42% 58
2022
Q4 		$4.67M Buy
112,318
+11,117
+11% +$477K 1.24% 30
2022
Q3 		$4.2M Buy
101,201
+6,701
+7% +$267K 1.19% 27
2022
Q2 		$3.09M Buy
+94,500
New +$3.44M 1.14% 29

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Parkman Healthcare Partners's PRCT Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of Procept Biorobotics (PRCT) in Q2 2023, closing a stake of 67,252 shares — an estimated $1.91M sold.

Parkman Healthcare Partners first reported a position in PRCT in Q2 2022 and held it in 4 quarters. The position peaked at $4.67M in Q4 2022. 120 funds tracked by Wall St. Rank hold PRCT as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining Procept Biorobotics position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 67,252 Procept Biorobotics shares in Q2 2023, an estimated $1.91M.
  • Parkman Healthcare Partners first reported a position in Procept Biorobotics in Q2 2022 and held it in 4 quarters.
  • Parkman Healthcare Partners's Procept Biorobotics position peaked at $4.67M in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.